On October 6, EVEREST MED rose 5.07% in regular trading, trading at 29.86 Hong Kong dollars per share, with a turnover of 16.24 million Hong Kong dollars.

The movement follows a Western Securities research report upgrading the stock to Buy, citing strong first-half performance driven by Nefecon sales and multiple pipeline catalysts.

The brokerage highlighted that first-half revenue reached 1.148 billion yuan, mainly from robust Nefecon sales growth, with non-IFRS adjusted profit turning positive at 97.23 million yuan. Additionally, expected approvals for Etripamil in the third quarter and LNZ100 in the first half of next year, along with the acceptance of Lupuzor's BLA filing, provide positive momentum.

EVEREST MED is a biopharmaceutical company focused on innovative drugs and vaccines across renal, anti-infective, and autoimmune disease areas.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)